Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Recent Pat Inflamm Allergy Drug Discov. 2011 Jan;5(1):26–36. doi: 10.2174/187221311794474883

Table 2. Clinical Trials of Drugs for the Treatment of Allergic Conjunctivitis*.

Clinical Trial ID Trail Purpose Drug Sponsor Indicated for Allergic Condition Phase
NCT01037179 An open-label, long-term study, with al-4943a ophthalmic solution, 0.2% in patients with allergic conjunctivitis Olopatadine Alcon Research Allergic conjunctivitis Phase III
NCT00891436 Study of the effect of fluticasone furoate nasal spray on spring allergy eye symptoms Fluticasone furoate Rush University Medical Center Allergic conjunctivitis to tree pollen or grass pollen Phase IV
NCT01012752 A multicenter study to evaluate safety and efficacy of specific immunotherapy with modified allergen extracts Modified allergen extract Roxall Medizin Allergic rhinitis and conjunctivitis Phase III
NCT00932607 SUBLIVAC® birch probe study Sublingual immunotherapy HAL Allergy Seasonal rhinitis, rhinoconjunctivitis and birch pollen allergy Phase II
NCT00831025 Olea europaea subcutaneous immunotherapy Biological: immunotherapy with modified extract of Olea europaea pollen Laboratories Leti, S.L. Allergy rhinoconjunctivitis Phase III